FDA considers expanded use of Xiaflex in Dupuytren's contracture
This article was originally published in Scrip
Executive Summary
The FDA has accepted for review Auxilium Pharmaceuticals' supplemental biologics license application (sBLA) for Xiaflex (collagenase clostridium histolyticum) to treat two Dupuytren's contracture cords concurrently – setting 20 October as the Prescription Drug User Fee Act action date.